Despite the growing body of literature, the evidence surrounding the CV efficacy of GLP-1 RAs, particularly semaglutide and exenatide, in patients with T2DM and established ASCVD remains scattered across multiple trials with varying outcome measures and study designs. This evidence concerns the gene GCG and atherosclerosis.